

AUTHOR INDEX

Volume 41

January to June 1990

Aedo, A-R, 569
 Allonen, H., 353, 485
 Alvarez-Sanchez, F., 169
 Anand, S., 323
 Ansari, S., 323
 Ashwell, E., 363
 Ball, M.J., 363
 Banerjee, A., 293, 301
 Baulieu, E.E., 85
 Blain, R., 605
 Blankenstein, M.A., 345
 Bleau, G., 605
 Borggaard, B., 259
 Brache, V., 169
 Butchart, A., 583
 Bygdeman, M., 283, 461
 Cafisch, C.R., 207
 Chakravarti, R.N., 179, 419
 Chaudhary, J., 641
 Chavinie, J., 221
 Cheng, J., 389
 Chi, I-c, 495
 Chiang, S.T., 39
 Chillik, C.F., 85
 Chitcharoenthum, M., 431
 Chompootawee, S., 507
 Cilenti, D., 9
 Cochon, L., 169
 Dada, O., 569
 Danforth, D.R., 623
 Das, R.P., 641
 Datta, J.K., 93
 Davidhazy, A., 591
 Demarest, K., 399
 De Plunkett, T.L., 221
 Dhall, K., 293, 301
 Dickmann, Z., 189
 Diczfalusy, E., 569
 Dominik, R., 495
 Dubois, C., 85
 DuBose, Jr., T.D., 207
 Dusitsin, N., 507
 Elger, W.A.G., 197
 El-Tawil, A., 317
 Epelboim, S., 221
 Fahmy, K., 317
 Fang, Q.L., 663
 Farooq, A., 323
 Farr, G., 495
 Faundes, A., 169
 Fotherby, K., 533, 557
 Fraser, H.M., 73

Fugere, P., 1
 Gao, J., 485
 Gates, D.S., 9
 Gaur, A., 301
 Gillmer, M.D.G., 363
 Goldstuck, N.D., 583
 Gottlieb, C., 461
 Gréen, K., 283, 461
 Gross, W., 245
 Grubb, G.S., 27
 Guha, S.K., 323
 Gupta, I., 179, 419
 Hahn, D., 623
 Hahn, D.W., 399
 Haspels, A.A., 345
 He, C-h, 557
 Heidt, F., 245
 Helm, P., 475
 Hingorani, V., 293, 301
 Ho, P.C., 55
 Hodgen, G.D., 85, 623
 Hofmeyr, G.J., 583
 Hsiao, J.G., 623
 Hu, W-W, 389
 Ibrahim, M., 317
 Ismail, H., 317
 Jackson, M., 363
 Jayawardena, K.G.I., 213
 Jia, M., 353
 Jivasak-Apimas, S., 9
 Johannisson, E., 569
 Juneja, R., 179, 419
 Jung-Hoffmann, C., 245
 Kharat, I., 293
 Kjaer, A., 259
 Klavon, S.L., 27
 Kloosterboer, H.J., 345
 Koetsawang, S., 9
 Krishna, U., 293, 301
 Kuhl, H., 245
 Kumar, G.P., 633
 Kumar, M., 519
 Kumar, S., 293, 301
 Kune, G.A., 19
 Kune, S., 19
 Kwan, M.S.W., 55
 Laloraya, M., 633
 Laloraya, M.M., 633
 Landgren, B-M, 569
 Lebech, A-M, 259
 Leckyim, N-A, 9
 Lewin, F., 221

CONTRACEPTION

Li, G.Y., 663
Li, L.S., 663
Li, M.F., 663
Liao, D-i, 557
Lidegaard, Ø., 475
Lin, Y.C., 431
Lindstedt, G., 271
Liu, Q.L., 617
Liu, W.T., 55
Lobo, R.A., 39
Lohiya, N.K., 519
Luo, H-z, 389
Luukkainen, T., 353, 485
Ma, Q.L., 663
Majumdar, N., 93
Majumdar, S., 179, 419
Majumdar, S.S., 641
Martin, A., 411
März, W., 245
Matlin, S.A., 557
Mauvis-Jarvis, P., 221
McGuire, J.L., 399, 623
Milsom, I., 271
Mori, A., 655
Mowszowicz, I., 221
Nagata, Y., 635
Nair, N.S., 293
Patil, R.K., 197
Phillips, A., 399
Pongubalan, J.M.R., 197
Puri, C.P., 197
Qian, S.Z., 617
Rådestad, A., 283
Ratnasooriya, W.D., 213, 441
Refn, H., 259
Reidenberg, M.M., 377
Rikihisa, Y., 431
Roberts, K.D., 605
Robinson, N., 495
Roh, S.I., 623
Roy, S., 293, 301
Rybo, G., 271
Sammour, M., 317
Sanyal, S.N., 179
Schierup, L., 259
Sethi, N., 333
Shahani, S.M., 293, 301
Sharma, D.N., 323
Sharma, K., 519
Sharma, N.C., 301
Sharma, R.K., 641
Sharma, S., 519
Sheridan, P., 605
Shi, F.J., 617
Shi, Y-e, 557
Sitruk-Ware, R., 221
Singh, O., 293, 301
Singh, R.K., 333
Sonnendecker, E.W.W., 383
Sonoda, T., 655
Spitz, I.M., 221
Srivastava, R.K., 333
Stanczyk, F.Z., 39
Stube, R., 591
Sun, B-1, 485
Suwanichati, S., 9
Swahn, M.L., 461
Swahney, H., 293
Takeuchi, K., 655
Talwar, G.P., 293, 301
Tang, Y.L., 617
Tejada, A.S., 169
Terranova, P.F., 189
Thalabard, J-C, 221
Thijssen, J.H.H., 345
Tournaire, M., 221
Ulmann, A., 85
Van der Vange, N., 345
Van Look, P.F.A., 557
Vézina, D., 605
Vickery, B.H., 411
Vince, P.M., 557
Voeller, B., 591
Wadsworth, R.M., 213, 441
Wali, A., 179, 419
Wallace, E.M., 63
Waller, D.P., 411
Wang, J-d, 389
Wang, S-1, 485
Wang, Y., 617
Watson, L.F., 19
Williams, R.F., 623
WHO Task Force on Long-Acting
Systemic Agents for Fertility
Regulation, 105, 125, 143, 151
Williams, R.F., 623
Wolf, J.P., 85
Wong, F., 399
Wu, D.F., 377
Wu, F.C.W., 63
Wu, J.T., 551
Wu, S-C, 485
Wu, X.M., 663
Xiao, B., 353
Xu, D.Z., 663
Xu, J-q, 557
Xu, R-h, 389
Yamamoto, S., 655
Yaneva, H., 221
Yang, Y.Q., 551
Zaneveld, L.J.D., 411
Zhang, H.Y., 663
Zhang, X., 353
Zhao, S-c, 453
Zhong, C.Q., 617
Zhou, L., 353
Zhu, P-d, 389
Zhu, Y-h, 557

SUBJECT INDEX

VOLUME 41

January to June 1990

Abortifacient, use of RU486, 221
Acceptability,
 levonorgestrel-releasing IUD, 485
 menfegol vaginal tablets, 507
 nonoxynol-9 vaginal tablets, 507
 Norplant^R-2, 485
Air Burst Test of condoms, cinematography of rupture, 591
Androgen receptor studies, various progestins (rat), 399
Androgenic activity, various progestins (rat), 399
Anesthetics + cycloheximide, synergism to achieve ovulation blockade (hamster), 189
Anodyne-lubricant jelly with dicaine, effect on cervical dilatation, 663
Anti-hCG immunization, effect on menstrual cycle, 293
Anti-hCG vaccine, clinical trial, 301
Anti-protamine antibodies, in vasectomized men, 605
Anti-sperm antibodies, in vasectomized men, 605
Antiprogestin,
 RU 486, 85, 221, 283, 461, 551
 ZK 98.299, 197
Arachidonic acid bioconversion, effect of RU 486, 283
Biphasic ethinylestradiol + desogestrel, effect on SHBG, CBG and testosterone levels, 345
Bleeding pattern,
 effect of levonorgestrel, 151
 levonorgestrel-releasing IUD, 353, 485
 Norplant^R-2, 485
 vaginal ring releasing levonorgestrel, 151
Body weight, effect of gossypol (rat), 431
Breakage of IUDs, fracture force measurements, 583
CA⁺⁺-APTase activity in sperm, effect of verapamil (guinea pig), 419
CA⁺⁺-uptake by sperm, effect of verapamil (guinea pig), 419
Calcium content of sperm, effect of verapamil (guinea pig), 419
Cancer of colon and rectum, association with use of oral contraceptives, 19
Carbohydrate metabolism, effect of triphasic contraceptives, 363
CBG (corticosteroid binding globulin)
CBG level, effect of combined oral contraceptives, 345
Cervical dilatation,
 Anodyne-lubricant jelly with dicaine, 663
 effect of lidocaine, 663
 effect of RU 486, 283

CONTRACEPTION

- Cervix,
 - effect of Cu T-200, 317
 - effect of Lippes loop, 317
- α -Chlorhydrin, effect on pH of testis and epididymis (rat), 207
- Clinical effects,
 - use of Multiload IUDs, 271
 - use of triphasic contraceptives, 259
- Clinical evaluation, RU486 used as an abortifacient, 221
- Clinical performance,
 - levonorgestrel-releasing IUD, 485
 - Norplant^R-2, 485
 - Nova-T, 1
- Clinical trial, anti-hCG vaccines, 301
- Coagulation proteins, effect of triphasic contraceptives, 363
- Cobalt chloride, effect on sperm motility and spermatozoal surfaces, 633
- Colorectal cancer and oral contraceptives use, 19
- Colposcopic findings, effect of IUD use, 317
- Condom, cinematography of burst during Air Burst Test, 591
- Contraceptive efficacy, tamoxifen (hamster), 93
- Contraceptive use, influence on pelvic inflammatory disease, 475
- Contraceptive vaccine,
 - Clinical trial, 301
 - effect on menstrual cycle, 293
- Copper 7, study on breakage forces, 583
- Copper T220, effect on endometrium, 389
- Cortisol level, effect of RU486, 221
- Cu T-200, cyto-colpo-pathological study, 317
- Cycloheximide + anesthetics, synergism to achieve ovulation blockade (hamster), 189
- Cytological findings, effect of IUD use, 317
- 17-Deacetylated norgestimate, progestational and androgenic receptor binding affinities (rat, rabbit), 399
- Detirelix,
 - effect on ovulatory cycle (monkey), 73
 - LHRH antagonist, 73
- Dilatation of cervix,
 - Anodyne-lubricant jelly with dicaine, 663
 - effect of lidocaine, 663
 - effect of RU 486, 283
- Discontinuation,
 - use of foaming vaginal tablets, 507
 - use of vaginal ring releasing levonorgestrel, 151
- Discontinuation rate, use of vaginal ring releasing levonorgestrel, 105, 125
- Effectiveness,
 - menfegol vaginal tablets, 507
 - nonoxynol-9 vaginal tablets, 507

- Efficacy,**
 - levonorgestrel-releasing IUD, 485
 - Norplant^R-2, 485
 - use of RU486 as an abortifacient, 221
 - use of vaginal ring releasing levonorgestrel, 105
- Egg transport, effect of RU 486 (mouse), 551
- Electrocoagulation, long-term follow-up following**
 - laparoscopic sterilization, 9
- Embryonic development, effect of RU 486 (mouse),** 551
- Embryos,**
 - effect of IUD-bearing uterine secretions (mouse), 655
 - effect of RU 486 (monkey), 85
- Enalapril, effect on sperm motility,** 213
- Endocervical cultures, use of Nova-T,** 1
- Endocrine status, effect of anti-hCG vaccines,** 301
- Endometrium,**
 - effect of GnRH antagonist + norgestimate (monkey), 623
 - effect of levonorgestrel, 569
 - effect of norethisterone, 569
 - morphometry of microvessels with use of IUDs, 389
- Epididymis, effect of α -chlorhydrin (rat),** 207
- Estradiol level,**
 - effect of anti-hCG vaccines, 301
 - effect of depot medroxyprogesterone acetate + testosterone oenanthate, 63
 - effect of GnRH antagonist + norgestimate (monkey), 623
 - effect of levonorgestrel, 169, 353, 569
 - effect of LHRH antagonist (monkey), 73
 - effect of norethisterone, 569
 - effect of RU 486, 221
 - effect of tamoxifen (hamster), 93
- Ethinylestradiol, pharmacokinetics,** 39
- Ethinylestradiol + cyproterone acetate, effect on SHBG, CBG and testosterone levels,** 345
- Ethinylestradiol + desogestrel,**
 - effect on serum lipids, 55
 - effect on serum lipids and lipoproteins, 245
 - effect on SHBG, CBG and testosterone levels, 345
- Ethinylestradiol + gestodene,**
 - clinical and hormonal effects, 259
 - effect on coagulation proteins, 363
 - effect on metabolism, 363
 - effect on serum lipids and lipoproteins, 245
- Ethinylestradiol + levonorgestrel,**
 - clinical and hormonal effects, 259
 - effect on coagulation proteins, 363
 - effect on metabolism, 363
 - effect on serum lipids, 55
 - effect on SHBG, CBG and testosterone levels, 345
 - pharmacokinetics, 39
- Ethinylestradiol + norethisterone, effect on SHBG, CBG and testosterone levels,** 345

CONTRACEPTION

Ethinylestradiol level, following administration of ethinylestradiol + levonorgestrel, 39
Ethynodiol + desogestrel, potency and pharmacokinetics, 533
Ethinodiol + gestodene, potency and pharmacokinetics, 533
Ethynodiol + levonorgestrel, potency and pharmacokinetics, 533
Ethynodiol + norethisterone, potency and pharmacokinetics, 533
Expulsion,
 Norplant^R implants, 27
 use of vaginal ring releasing levonorgestrel, 125
Expulsion rate, Nova-T, 1
Ferritin concentration, effect of Multiload IUDs, 271
Fertility,
 effect of ketoconazole (rat), 411
 effect of prazosin (rat), 441
Foetal outcome, effect of antiprogestin ZK 98.299 (monkey), 197
Food intake, effect of gossypol (rat), 431
Fracture forces, study on breakage of IUDs, 583
FSH level,
 effect of GnRH antagonist + norgestimate (monkey) 623
 effect of levonorgestrel, 569
 effect of LHRH antagonist (monkey), 73
 effect of norethisterone, 569
Gestagens,
 pharmacokinetics and pharmacodynamic effects, 533
 potency, 533
 serum binding, 533
 serum concentrations, 533
Gestodene, progestational and androgenic receptor binding affinities (rat, rabbit), 399
Gestodene level, following administration of ethinylestradiol + gestodene, 259
GnRH (gonadotropin releasing hormone)
GnRH antagonist + norgestimate,
 effect on endometrium and ovary (monkey), 623
 effectiveness as contraceptive (monkey), 623
Gossypol,
 effect on sperm and hypokalemia (monkey), 519
 effect on sperm function, 617
 effect on thyroid function (rat), 431
 stereoselective activity (rat), 377
Gossypol + potassium chloride, effect on sperm and hypokalemia (monkey), 519
HCG level, effect of RU486, 221
Hematological parameters,
 effect of anti-hCG vaccines, 301
 effect of Multiload IUDs, 271
Hemolytic effects, gossypol (rat), 377
Histological findings, effect of IUD use, 317

CONTRACEPTION

Histological studies, effect of RU486 used as an abortifacient, 221

Hormonal effects, use of triphasic contraceptives, 259

Hormone levels, effect of gossypol, 617

Hulka clip, long-term follow-up following laparoscopic sterilization, 9

Hypokalemia, effect of gossypol with potassium chloride (monkey), 519

Immunization with anti-hCG vaccine, clinical trial, 301 effect on menstrual cycle, 293

Implant contraceptive, levonorgestrel, 27, 169, 485

Infection, insertion site of Norplant^R system, 27

Insertion site complications, use of Norplant^R system, 27

Intrauterine device (IUD),
 copper 7, 583
 copper T220, 389
 Cu T-200, 317
 levonorgestrel-releasing, 353, 389, 485
 Lippes Loop, 317
 MLCu-250, 271, 583
 MLCu-375, 271, 583
 Nova-T, 1, 583
 stainless steel ring, 389

Iron status, effect of Multiload IUDs, 271

Isomers of gossypol, study of stereoselective activity (rat), 377

IUD (intrauterine device)

IUD insertions, effect of uterine position, 495

IUD performance, effect of uterine position, 495

IUD thread, male partner complaint, 341

IUD-bearing uterine secretions, effect on embryos (mouse), 655

IUD-related infection, 341

3-Keto desogestrel, progestational and androgenic receptor binding affinities (rat, rabbit), 399

3-Keto norgestimate, progestational and androgenic receptor binding affinities (rat, rabbit), 399

Ketoconazole,
 effect on fertility (rat), 411
 effect on sperm (rat), 411

Laparoscopic sterilization, long-term follow-up, 9

Levonorgestrel,
 effects on pituitary, ovary and endometrium, 569
 pharmacokinetics, 39, 557
 progestational and androgenic receptor binding affinities (rat, rabbit), 399
 use as postcoital contraceptive, 557

CONTRACEPTION

- Levonorgestrel intravaginal ring,
 - bleeding patterns, 151
 - contraceptive efficacy, 105
 - discontinuation rate, 105, 125
 - expulsions, 125
 - pregnancy rate, 105, 143
 - relationship between pregnancy rate and body weight, 143
 - removals, 125
 - side effects, 105
- Levonorgestrel level,
 - following administration of ethinylestradiol + levonorgestrel, 39, 259
 - following administration of two formulations of levonorgestrel tablets, 557
 - following use of levonorgestrel-releasing IUD, 353
- Levonorgestrel-releasing IUD,
 - clinical trial, 485
 - effect on endometrium, 389
 - pharmacokinetic and pharmacodynamic studies, 353
- LH level,
 - effect of GnRH antagonist + norgestimate (monkey), 623
 - effect of levonorgestrel, 569
 - effect of LHRH antagonist (monkey), 73
 - effect of norethisterone, 569
- LHRH (luteinizing hormone releasing hormone)
- LHRH antagonist,
 - detirelix, 73
 - effect on ovulatory cycle (monkey), 73
- Lidocaine, effect on cervical dilatation, 663
- Lipid levels, effect of triphasic contraceptives, 363
- Lipid metabolism,
 - effect of depot medroxyprogesterone acetate + testosterone oenanthate, 63
 - effect of ethinylestradiol + desogestrel, 55, 245
 - effect of ethinylestradiol + gestodene, 245
 - effect of ethinyl oestradiol + levonorgestrel, 55
- Lippes loop, cyto-colpo-pathological study, 317
- Local reaction, insertion site of Norplant® system, 27
- Male contraceptive,
 - α -chlorhydrin (rat), 207
 - depot-medroxyprogesterone acetate + testosterone oenanthate, 63
- Medroxyprogesterone acetate + testosterone oenanthate,
 - effect on hormone levels, 63
 - effect on serum lipoproteins, 63
- Medroxyprogesterone acetate level, following administration of depot medroxyprogesterone acetate + testosterone oenanthate, 63
- Menfegol vaginal tablets, evaluation of safety, effectiveness and acceptability, 507
- Menstrual blood loss, effect of Multiload IUDs, 271

CONTRACEPTION

Menstrual cycle,
 effect of anti-hCG vaccines, 293
 effect of levonorgestrel, 569
 effect of norethisterone, 569

Metabolic parameters, effect of anti-hCG vaccines, 301

Metabolism, effect of triphasic contraceptives, 363

9-Methylene PGE₂ + RU 486, use for termination of pregnancy, 461

MLCu 250/375, study on breakage forces, 583

Morphometric study of endometrium, use of IUDs, 389

Multiload IUDs,
 effect of uterine position on insertions and performance, 495
 effect on menstrual blood loss and iron status, 271

Nal-Glu GnRH antagonist + norgestimate, effectiveness as contraceptive (monkey), 623

Nonoxynol-9 vaginal tablets, evaluation of safety, effectiveness and acceptability, 507

Norethisterone, effects on pituitary, ovary and endometrium, 569

Norgestimate,
 progestational and androgenic activities (rat, rabbit), 399
 progestational and androgenic receptor binding affinities (rat, rabbit), 399

Norgestimate + Nal-Glu GnRH antagonist, effectiveness as contraceptive (monkey), 623

Norplant^R,
 effect on ovarian endocrine function, 169
 insertion site complications during use, 27

Norplant^R-2, clinical trial, 485

Nova-T,
 clinical performance, 1
 study on breakage forces, 583

Occlusion of vas deferens,
 percutaneous injection of polyurethane elastomer plug, 453
 use of styrene maleic anhydride (monkey), 323
 use of styrene maleic anhydride (rat), 333

Oral contraceptive,
 biphasic ethinylestradiol + desogestrel, 345
 ethinylestradiol + cyproterone acetate, 345
 ethinylestradiol + desogestrel, 55, 245, 345, 533
 ethinylestradiol + gestodene, 245, 533
 ethinylestradiol + levonorgestrel, 55, 345, 533
 ethinylestradiol + norethisterone, 345, 533
 triphasic ethinylestradiol + gestodene, 259, 345, 363
 triphasic ethinylestradiol + levonorgestrel, 39, 259, 345, 363

Oral contraceptive use and colorectal cancer, 19

Ovarian endocrine function, effect of norgestrel, 169

Ovary, effect of GnRH antagonist + norgestimate (monkey), 623

Ovulation blockage, synergism of cycloheximide and anesthetics (hamster), 189

CONTRACEPTION

Ovulatory cycle, effect of LHRH antagonist (monkey), 73
Pelvic inflammatory disease, influence of contraceptive, sexual and social life events, 475
Penile pain, IUD thread, 341
Percutaneous injection of polyurethane elastomer plug, vas deferens occlusion, 453
pH in seminiferous tubules and epididymal duct, effect of α -chlorhydrin (rat) 207
Pharmaceutical characteristics, two formulations of levonorgestrel tablets, 557
Pharmacokinetic and pharmacodynamic studies, levonorgestrel-releasing IUD, 353
Pharmacokinetic parameters, two formulations of levonorgestrel tablets, 557
Pharmacokinetics, ethinylestradiol + levonorgestrel, 39
gestagens, 533
Polyurethane elastomer occlusion of vas deferens, recovery of fertility after removal, 453
Polyurethane elastomer plug, percutaneous injection for vas deferens occlusion, 453
Postcoital contraceptive, levonorgestrel, 557
Potassium chloride + gossypol, effect on sperm and hypokalemia (monkey), 519
Potassium level, effect of gossypol (monkey), 519
effect of gossypol + potassium chloride (monkey), 519
Potency, gestagens, 533
Prazosin, effect on fertility (rat), 441
Pregnancy, effect of antiprogestin ZK 98.299 (monkey), 197
Pregnancy rate, Nova-T, 1
use of vaginal ring releasing levonorgestrel, 105, 143
Pregnancy rate and weight relationship, use of vaginal ring releasing levonorgestrel, 143
Progestational activity, various progestins (rabbit), 399
Progesterone, effect on RU 486-treated embryos (monkey), 85
progestational and androgenic receptor binding affinities (rat, rabbit), 399
Progesterone antagonist, effect on foetal outcome (monkey), 197
effect on pregnancy (monkey), 197
ZK 98.299, 197
Progesterone level, effect of anti-hCG vaccines, 301
effect of GnRH antagonist + norgestimate (monkey), 623
effect of levonorgestrel, 169, 353, 569
effect of LHRH antagonist (monkey), 73
effect of norethisterone, 569
effect of RU486, 221
effect of tamoxifen (hamster), 93
effect of ZK 98.299 (monkey), 197

CONTRACEPTION

Progesterin receptor studies, various progestins (rabbit), 399
Progestins, progestational and androgenic receptor binding affinities (rat, rabbit), 399
Progesterogens, hormonal and endometrial effects, 569
Prostaglandin analogue, 9-methylene PGE₂, 461
Protamine sulfate administration, effect on vasectomized men, 605
Removal rate, Nova-T, 1
Removals, use of vaginal ring releasing levonorgestrel, 125
Reproductive parameters, effect of prazosin (rat), 441
RU 486,
 effect on egg transport (mouse), 551
 effect on embryo development (mouse), 551
 effect on embryos (monkey), 85
 effect on uterine cervix, 283
 use as abortifacient, 221
RU 486 + 9-methylene PGE₂, use for termination of pregnancy, 461
RU 486 level, following administration of RU486 as an abortifacient, 221
Rupture of condoms, cinematography of burst during Air Burst Test, 591
Safety,
 menfegol vaginal tablets, 507
 nonoxynol-9 vaginal tablets, 507
Secretions from IUD-bearing uterus, effect on embryos (mouse), 655
Seminal plasma, effect of STS-557 (monkey), 641
Seminology,
 effect of gossypol (monkey), 519
 effect of gossypol + potassium chloride (monkey), 519
Sexual parameters, influence on pelvic inflammatory disease, 475
SHBG (sex hormone binding globulin)
SHEG level,
 effect of combined oral contraceptives, 345
 effect of depot medroxyprogesterone acetate + testosterone oenanthate, 63
 effect of ethinylestradiol + gestodene, 259
 effect of ethinylestradiol + levonorgestrel, 259
 effect of levonorgestrel, 557
 effect of triphasic contraceptive, 363
Side effects,
 use of levonorgestrel-releasing IUD, 485
 use of Norplant^R-2, 485
 use of RU486 as an abortifacient, 221
 use of vaginal ring releasing levonorgestrel, 105
Social parameters, influence on pelvic inflammatory disease, 475
Sodium level,
 effect of gossypol (monkey), 519
 effect of gossypol + potassium chloride (monkey), 519

CONTRACEPTION

- Sperm count,
 - effect of ketoconazole (rat), 411
 - effect of STS-557 (monkey), 641
 - effect of verapamil (guinea pig), 179
- Sperm function, long after cessation of gossypol treatment, 617
- Sperm motility,
 - effect of cobalt chloride and recovery with cysteine, 633
 - effect of enalapril, 213
 - effect of ketoconazole (rat), 411
 - effect of STS-557 (monkey) 641
 - effect of verapamil (guinea pig), 179
- Spermatozoa,
 - effect of cobalt chloride, 633
 - effect of STS-557 (monkey), 61
 - effect of verapamil (guinea pig), 419
- Spermatozoal functions, effect of verapamil (guinea pig), 179
- Stainless steel ring, effect on endometrium, 389
- Stereoselective activity, gossypol (rat), 377
- Sterilization,
 - Hulka clip, 9
 - tubal ring occlusion, 9
 - unipolar electrocoagulation, 9
- STS-557, effect on spermatozoa (monkey), 641
- STS-557 level, following administration of STS-557 (monkey), 641
- Styrene maleic anhydride,
 - effect of vas deferens (rat), 333
 - use for vas deferens occlusion (monkey), 323
- Synergism of cycloheximide with anesthetics, effect on ovulation (hamster), 189
- T-shaped copper IUDs, effect of uterine position on insertions and performance, 495
- Tamoxifen, contraceptive efficacy (hamster), 93
- Termination of pregnancy, use of RU 486 + 9-methylene PGE₂, 461
- Testis,
 - effect of α -chlorhydrin (rat), 207
 - effect of verapamil (guinea pig), 179
- Testosterone level,
 - effect of combined oral contraceptives, 345
 - effect of gossypol (monkey), 519
 - effect of gossypol + potassium chloride (monkey), 519
 - effect of STS-557 (monkey), 641
 - following administration of depot medroxyprogesterone acetate + testosterone oenanthate, 63
- Thyroid function, effect of gossypol (rat), 431
- Transaminase activity,
 - effect of gossypol (monkey), 519
 - effect of gossypol + potassium chloride (monkey), 519

CONTRACEPTION

Triphasic ethinylestradiol + gestodene,
 clinical and hormonal effects, 259
 effect on coagulation proteins, 363
 effect on metabolism, 363
 effect on SHBG, CBG and testosterone levels, 345

Triphasic ethinylestradiol + levonorgestrel,
 clinical and hormonal effects, 259
 effect on coagulation proteins, 363
 effect on metabolism, 363
 effect on SHBG, CBG and testosterone levels, 345
 pharmacokinetics, 39

Tubal ring occlusion, long-term follow-up following
 laparoscopic sterilization, 9

Uterine contractility, effect of RU 486 + 9-methylene
 PGE₂, 461

Uterine enzymes, effect of tamoxifen (hamster), 93

Uterine position, effect on insertions and performance of
 IUDs, 495

Uterine secretions of IUD-bearing uterus,
 effect on embryos (mouse), 655
 leucocyte count (mouse), 655
 prostaglandin levels (mouse), 655

Vaginal contraceptive,
 menfegol tablets, 507
 nonoxynol-9 tablets, 507

Vaginal ring, releasing levonorgestrel, 105, 125, 143, 151

Vas deferens, effect of styrene maleic anhydride (rat), 333

Vas deferens occlusion,
 percutaneous injection of polyurethane elastomer
 plug, 453
 use of styrene maleic anhydride (monkey), 323

Vasectomized men, effect of protamine sulfate
 administration, 605

Verapamil,
 effect on spermatozoa (guinea pig), 419
 effect on spermatozoal functions (guinea pig), 179

Weight and pregnancy rate relationship, use of vaginal ring
 releasing levonorgestrel, 143

ZK 98.299,
 effect on foetal outcome (monkey), 197
 effect on pregnancy (monkey), 197